Tag: Second-generation fast skeletal muscle troponin activator (FSTA) selective for fast skeletal muscle fibers

  • Reldesemtiv

    Second-generation fast skeletal muscle troponin activator (FSTA) selective for fast skeletal muscle fibers

    A next-generation fast skeletal muscle troponin activator developed by Cytokinetics to amplify skeletal muscle force output through calcium sensitization of the sarcomere, evaluated in Phase 2 and Phase 3 clinical trials in amyotrophic lateral sclerosis and spinal muscular atrophy.

    Abstract

    Reldesemtiv (CK-2127107) is a small-molecule fast skeletal muscle troponin activator (FSTA) that selectively binds the regulatory troponin complex in fast skeletal muscle fibers, slows the rate of calcium release from troponin C, and thereby sensitizes the sarcomere to calcium at submaximal stimulation frequencies. The compound was discovered at Cytokinetics, Inc. through property-based optimization of a high-throughput screening hit, yielding improved free exposure, in vivo muscle activation potency, and tolerability relative to the first-generation FSTA tirasemtiv, which had failed the Phase 3 VITALITY-ALS trial primarily because of dose-limiting tolerability (dizziness, nausea, weight loss, insomnia) and a 34.2 percent treatment discontinuation rate. Reldesemtiv does not activate slow skeletal or cardiac troponin complexes, providing a selectivity basis for its intended use in conditions characterized by fast skeletal muscle weakness secondary to attenuated neuronal input, including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and chronic obstructive pulmonary disease. In a Phase 1 pharmacodynamic study in 16 healthy volunteers, reldesemtiv amplified the tibialis anterior force-frequency response by approximately 60 percent at 10 Hz nerve stimulation at the highest plasma concentrations tested, confirming the mechanism of action in human skeletal muscle. Pharmacokinetics across five Phase 1 studies demonstrated dose-proportional exposure with a terminal half-life of approximately 5 to 14 hours depending on dose, a time to peak concentration of 2 to 3 hours, and similar pharmacokinetic profiles in young and elderly subjects. The primary analysis showed a mean difference of negative 1.1 points (95 percent CI, negative 2.17 to negative 0.08; p=0.04), numerically favoring placebo. No preplanned subgroup favored reldesemtiv. The compound is not approved by any regulatory authority for any indication. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.